Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NovaBay Pharmaceuticals (NBY) Revenue (2016 - 2025)

Historic Revenue for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to $521000.0.

  • NovaBay Pharmaceuticals' Revenue changed N/A to $521000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 6349.79%. This contributed to the annual value of $9.8 million for FY2024, which is 644.67% down from last year.
  • NovaBay Pharmaceuticals' Revenue amounted to $521000.0 in Q3 2025.
  • NovaBay Pharmaceuticals' 5-year Revenue high stood at $9.8 million for Q4 2024, and its period low was $521000.0 during Q3 2025.
  • In the last 5 years, NovaBay Pharmaceuticals' Revenue had a median value of $2.4 million in 2023 and averaged $3.0 million.
  • As far as peak fluctuations go, NovaBay Pharmaceuticals' Revenue crashed by 5111.52% in 2023, and later soared by 36554.02% in 2024.
  • Over the past 5 years, NovaBay Pharmaceuticals' Revenue (Quarter) stood at $3.2 million in 2021, then grew by 14.81% to $3.6 million in 2022, then crashed by 42.33% to $2.1 million in 2023, then soared by 365.54% to $9.8 million in 2024, then crashed by 94.67% to $521000.0 in 2025.
  • Its last three reported values are $521000.0 in Q3 2025, $9.8 million for Q4 2024, and $2.4 million during Q2 2024.